Emerging targets for positron emission tomography imaging in proteinopathies-Reference-Cited by-同舟云学术

Emerging targets for positron emission tomography imaging in proteinopathies

Published:2024-08-21 Issue:1 Volume:2 Page:
ISSN:2948-197X
Container-title:npj Imaging
language:en
Short-container-title:npj Imaging

Author:

Chassé Melissa,Vasdev Neil

Abstract

AbstractPositron emission tomography (PET) imaging of neurodegenerative disease has historically focused on a small number of established targets. The development of selective PET radiotracers for novel biological targets enables new ways to interrogate the neuropathology of proteinopathies and will advance our understanding of neurodegeneration. This perspective aims to highlight recent PET radiotracers developed for five emerging targets in proteinopathies (i.e., mHTT, BACE1, TDP-43, OGA, and CH24H).

Funder

Canadian Institutes of Health Research

Canada Research Chairs

Azrieli Foundation

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s44303-024-00032-4.pdf

Reference55 articles.

1. Golde, T. E. et al. Thinking laterally about neurodegenerative proteinopathies. J. Clin. Invest. 123, 1847–1855 (2013).

2. Pievani, M. et al. Brain connectivity in neurodegenerative diseases—from phenotype to proteinopathy. Nat. Rev. Neurol. 10, 620–633 (2014).

3. Bayer, A. T. Proteinopathies, a core concept for understanding and ultimately treating degenerative disorders? Eur. Neuropsychopharmacol. 25, 713–724 (2015).

4. Kovacs, G. G. Molecular pathology of neurodegenerative diseases: principles and practice. J. Clin. Pathol. 72, 725–735 (2019).

5. Kovacs, G. G. Are comorbidities compatible with a molecular pathological classification of neurodegenerative diseases? Curr. Opin. Neurol. 32, 279–291 (2019).